The report, now available on ASDReports, recognizes the following companies as the key players in the Global Gastric Cancer Drugs Market: Hoffmann-La Roche, Eli-lilly, Sanofi and Otsuka Holdings
Other Prominent Vendors in the market are: Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Commenting on the report, an analyst said: “The dominance of the market by the usage of off-label drugs to treat gastric cancer patients is one of the trends, and is expected to be a preferred treatment option for the medical fraternity, patients, and the families of patients. This will in turn raise the number of treatment-seeking patients, which will result in an overall increase in consumption of medicines.”
According to the report, the presence of growing unmet needs for appropriate drugs are one of the major factors propelling the growth of the market.
Further, the report states that the shortage of drugs decreases the revenue generated by individual drugs. In addition, a shortage of drugs may lead to delays of chemotherapeutic treatments, thereby promoting the use of expensive and alternative treatments that are less efficacious and safe.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.